Home › Funds › DME Capital Management, LP › IMVT
DME Capital Management, LP position in IMVT
IMMUNOVANT INC · Health Care
DME Capital Management, LP reported holding 70,140 shares of IMVT (IMMUNOVANT INC) in its Q3 2026 13F filing — a position valued at US$2.4M, representing 0.07% of its reported portfolio and ranking #42 among its reported holdings. DME Capital Management, LP has disclosed IMVT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How DME Capital Management, LP's IMVT position evolved
DME Capital Management, LP first disclosed a stake in IMVT in Q1 2026 at 93,520 shares (US$2.3M). The position peaked in Q2 2026 at 93,520 shares, worth US$3.6M. Across 3 filings, DME Capital Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 70,140 shares valued at US$2.4M — a reduction of -23,380 shares quarter over quarter.. Notable position changes include a 25% trim in Q3 2026 (shares fell 1% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 93.52K | $2.32M | New |
| Q2 2026 | 93.52K | $3.60M | Hold |
| Q3 2026 | 70.14K | $2.37M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMVT and 13F data
IMVT (IMMUNOVANT INC) is a Health Care company. 36 other funds we track also report a position in IMVT — the largest reported positions include Deep Track Capital, LP (US$309.5M), Farallon Capital Management (US$223.7M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$218.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMVT
- Deep Track Capital, LP 9.16M sh · $309.45M · Q3 2026
- Farallon Capital Management 5.80M sh · $223.67M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.47M sh · $218.59M · Q3 2026
- Two Seas Capital LP 4.61M sh · $155.82M · Q3 2026
- TCG Crossover Management, LLC 4.46M sh · $150.59M · Q3 2026
- RTW INVESTMENTS, LP 3.18M sh · $107.35M · Q3 2026
- BAKER BROS. ADVISORS LP 2.77M sh · $93.58M · Q3 2026
- ADAR1 Capital Management, LLC 2.12M sh · $71.46M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.62M sh · $54.89M · Q3 2026
- Alpine Global Management, LLC 1.37M sh · $46.26M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 624.05K sh · $21.08M · Q3 2026
More on DME Capital Management, LP
FAQ
How long has DME Capital Management, LP held IMVT?
DME Capital Management, LP has disclosed IMVT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is DME Capital Management, LP's current position in IMVT?
As of Q3 2026, DME Capital Management, LP holds 70.14K shares of IMVT (IMMUNOVANT INC), valued at $2.37M, representing 0.07% of its reported portfolio and ranking #42.
Has DME Capital Management, LP been buying or selling IMVT?
In the latest 13F filing (Q3 2026), DME Capital Management, LP reduced its position in IMVT. The position peaked in Q2 2026 at 93.52K shares.
Which other funds hold IMVT?
Other major institutional holders of IMVT include Deep Track Capital, LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.